Literature DB >> 1969223

Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects on hemodynamics and urine output.

G Baumann1, S B Felix, S A Filcek.   

Abstract

The hemodynamic effects of dopexamine hydrochloride and dobutamine were compared during dose-response infusions of dopexamine (1.0 to 4.0 micrograms/kg/min) and dobutamine (2.5 to 10.0 micrograms/kg/min) and during 48-hr infusions at doses producing initial matched increases in cardiac output. Thirty-three patients with severe, stable, chronic congestive heart failure (CHF) (New York Heart Association class III to IV) participated. Both drugs produced an increase in cardiac index, brought about by increased stroke volume index and heart rate, and systemic vasodilatation. The relative contribution of these mechanisms differed, dopexamine proving the more potent vasodilator. The effects of dopexamine were maintained without variation during the 48-hr infusion, apart from a reduction in the increase in heart rate. The effects of dobutamine, while remaining above control at most time-points during the 48-hr infusion, attenuated toward control values. Dopexamine also appeared to promote increased urine output and creatinine clearance during the 48-hr infusion. Both drugs were well tolerated. Dopexamine elicited larger peak hemodynamic effects at dosages that had equivalent effects on cardiac output, and favorable renal responses, and demonstrated no long-term attenuation of effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969223     DOI: 10.1016/0002-9149(90)91382-g

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Inotropic support of the critically ill patient. A review of the agents.

Authors:  P J Kulka; M Tryba
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

2.  Circulatory and diuretic effects of dopexamine infusion in low-birth-weight infants with respiratory failure.

Authors:  P Kawczynski; A Piotrowski
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

Review 3.  Risks and benefits of the treatment of heart failure. Current status.

Authors:  J F Moran
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

4.  Evaluation of the effects of dopexamine, a novel DA1 receptor and beta 2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock.

Authors:  M S Chintala; R J Moore; M F Lokhandwala; B S Jandhyala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

5.  Renal effect of dopexamine hydrochloride in patients with chronic renal dysfunction.

Authors:  M M Atallah; M M Saied; T A el-Diasty; P A Gray; G R Park
Journal:  Urol Res       Date:  1992

6.  Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, beta 1- and beta 2-receptor-mediated responses.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

7.  Arrhythmogenic potential of dopexamine hydrochloride during halothane anaesthesia in dogs.

Authors:  S M Neustein; I Dimich; I Sampson; A Sadeghi; C Mezrow; H Shiang
Journal:  Can J Anaesth       Date:  1994-06       Impact factor: 5.063

Review 8.  Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.